Neurocrine Biosciences Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
50.64+0.31 (+0.62%)
At close: 4:00 PM EDT
People also watch:
ALKSLGNDPGNXNKTRINCY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open50.49
Prev Close50.33
Bid0.00 x
Ask54.91 x 1000
Day's Range50.00 - 51.74
52wk Range31.25 - 58.46
1y Target EstN/A
Market Cap4.39B
P/E Ratio (ttm)-35.46
Beta0.05
Volume941,772
Avg Vol (3m)739,175
Dividend & Yield0.00 (0.00%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : September 30, 2016
    Capital Cube18 hours ago

    Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US : September 30, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
    Insider Monkey9 days ago

    Blue Jay Capital Betting On Big Returns From These Healthcare Stocks

    Founded by Paul Sinclair in August 2014, Blue Jay Capital Management is a healthcare-focused hedge fund based in California. Prior to founding Blue Jay Capital (named after Canada’s only current Major League Baseball team, the Toronto Blue Jays), Mr. Sinclair founded and ran another healthcare-focused hedge fund Expo Capital Management (named after the former Canadian MLB team the Montreal […]

  • PR Newswire23 days ago

    Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference

    SAN DIEGO, Sept. 7, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at the Morgan Stanley Healthcare Conference in New York City. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.